Clinical trials
High Bleeding Risk clinical trials
Below are recruiting high bleeding risk clinical trials, each written for real people, not researchers. We’re tracking 143 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06221670RecruitingPhase 2
Toripalimab after surgery for high-risk early lung cancer
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT07671378RecruitingPhase 2
Study of zanubrutinib plus sonrotoclax for high-risk CLL/SLL
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
Nanjing, JiangsuAges 18–75 - NCT06143969Recruiting
Ultrasound-guided clot-dissolving treatment for intermediate-high risk pulmonary embolism
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
Milan, ItaliaAges 18 years+ - NCT06120387Recruiting
Radiation after kidney-sparing surgery for high-risk ureteral cancer
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
BeijingAges 18 years+ - NCT06036446Recruiting
Late cerclage for preventing early birth in high-risk pregnancies
This trial tests if placing a stitch in the cervix (cerclage) between 24 and 27 weeks of pregnancy can help prevent preterm birth in women whose cervix is short. It may be an option for those who find out late in pregnancy that they are at risk.
Charlotte, North CarolinaAges 18–50 - NCT05984537RecruitingPhase 4
Bivalirudin during angioplasty for high-risk heart plaques
This study tests whether a blood thinner called bivalirudin, given during a procedure to open blocked heart arteries (PCI), helps blood flow better in the tiny vessels of the heart afterward. It is for people with a recent unstable heart condition and a high-risk plaque seen on a CT scan.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05936606Recruiting
Personalized blood thinner choice after stent placement
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
SeoulAges 19–80 - NCT05920863RecruitingPhase 2
Lenvatinib, immunotherapy, plus liver artery treatment before surgery
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hangzhou, ZhejiangAges 18–75 - NCT05895136RecruitingPhase 2
Albumin plus blood thinner for severe cirrhosis after hospital recovery
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
ClichyAges 18–80 - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT05712200RecruitingPhase 3
Abelacimab for atrial fibrillation when blood thinners aren’t suitable
This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.
Birmingham, AlabamaAges 65 years+ - NCT05686434RecruitingPhase 2
Osimertinib after surgery for early-stage EGFR-mutated lung cancer
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07436741RecruitingPhase 3
Study of surufatinib plus chemo before surgery for pancreatic cancer
This trial tests if adding surufatinib to standard chemotherapy before surgery can help people with a certain type of pancreatic cancer. The goal is to see if the combination shrinks the tumor more than chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT05489289RecruitingPhase 3
AK104 to prevent HCC coming back after surgery
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05334784Enrolling by invitation
Heart pump study for planned high-risk heart stent procedures
This study looks at using a temporary heart pump called Impella ECP during planned high-risk heart stent procedures (PCI). It may help doctors support the heart more safely while placing the stents.
Phoenix, ArizonaAges 18–90 - NCT05287321RecruitingPhase 3
Aspirin plus hydroxychloroquine to prevent preeclampsia in high-risk pregnancy
This trial tests whether adding aspirin and hydroxychloroquine can lower the risk of preeclampsia during pregnancy in people considered high-risk. If you qualify, you may be assigned to take the study medicines to help protect you and the baby.
SeoulAges 19–50 - NCT05208307RecruitingPhase 2
Belantamab with pomalidomide and dexamethasone after high-risk myeloma transplant
This Phase 2 study tests a treatment combination (belantamab mafodotin, pomalidomide, and dexamethasone) for high-risk multiple myeloma after an autologous stem cell transplant. It aims to improve disease control in people who have certain genetic features or aggressive disease behavior.
Atlanta, GeorgiaAges 18 years+ - NCT05198960RecruitingPhase 3
Blood thinner drugs vs aspirin to prevent clot problems
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
AngersAges 18 years+ - NCT05139095RecruitingPhase 2
Camrelizumab plus apatinib for high-risk pregnancy tumor
This Phase 2 trial studies whether combining camrelizumab (an immune medicine) with apatinib (a medicine that blocks blood-vessel growth) can improve treatment for women with high-risk gestational trophoblastic neoplasia (GTN) that is very high-risk, or has returned or resisted chemotherapy. It may help shrink the tumor and reduce the chance it comes back by using two different approaches together.
BeijingAges 18–60 - NCT07363161Recruiting
Drug-coated balloon vs. stent for high-risk heart disease
This trial compares two treatments for people with complex coronary artery disease who have high-risk conditions or complicated blockages: a drug-coated balloon (DCB) versus a drug-eluting stent (DES). Both are ways to open up narrowed arteries and keep them open without surgery.
HomburgAges 18 years+ - NCT05040360RecruitingPhase 2
Chemotherapy after surgery for high-risk pancreatic NET tumors
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
Anchorage, AlaskaAges 18 years+ - NCT05055063RecruitingPhase 1
Belantamab for high-risk smoldering myeloma safety and early benefit
This Phase 1 trial tests belantamab mafodotin, a cancer medicine, in people with high-risk smoldering multiple myeloma to see how safe it is and whether it may shrink or control the disease. Because it’s an early-stage study, you would be closely monitored and treated with one main study drug.
Houston, TexasAges 18 years+
Hear when a new High Bleeding Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high bleeding risk?
- Yes. Clin2 currently lists 143 recruiting high bleeding risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high bleeding risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high bleeding risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.